This inventor holds 2 USPTO granted patents and 5 published patent applications and 1 EPO patent. Top assignee: Ip2ipo Innovations Limited. Active years: 2022-2025.
Company Filing History:
Years Active: 2022-2025
Title: Martin Wilkins: Innovator in Antibody Therapeutics
Introduction
Martin Wilkins is a distinguished inventor based in London, GB. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic agents for hypoxia-related diseases. With a total of 2 patents, his work has the potential to impact the treatment of conditions such as pulmonary hypertension and cancer.
Latest Patents
Wilkins' latest patents include the ZIP12 antibody, which relates to the development of antibodies that can be used in therapeutic and diagnostic applications. This invention extends to compositions that include these antibodies, such as pharmaceutical formulations and kits. Additionally, he has developed a patent focused on the identification of therapeutic agents for the treatment, diagnosis, and prevention of pulmonary hypertension.
Career Highlights
Throughout his career, Martin Wilkins has worked with notable companies, including Ip2ipo Innovations Limited and Imperial Innovations Limited. His expertise in biotechnology and therapeutic development has positioned him as a key figure in his field.
Collaborations
Wilkins has collaborated with esteemed colleagues, including Lan Zhao and Eduardo Oliver-Perez, contributing to advancements in therapeutic research and development.
Conclusion
Martin Wilkins is a prominent inventor whose work in antibody therapeutics holds promise for improving treatment options for serious health conditions. His innovative patents and collaborations reflect his commitment to advancing medical science.